Is Venetoclax a targeted drug or a chemotherapy drug?

Venetoclax (Venetoclax) is a targeted therapy, not chemotherapy. Chemotherapy is defined as a drug treatment that kills fast-growing cells in the body, which means it often kills other fast-growing normal cells in the body, such as red blood cells and cells in hair. Venecurate works by binding to a specific protein called BCL-2.

By binding to BCL-2, a protein that is overexpressed in cancer cells in people with cancers such as acute myeloid leukemia and chronic lymphocytic leukemia, venetoclax kills cancerous acute myeloid leukemia and chronic lymphocytic leukemia lymphocytes but not other types of cells. Veneclat is approved to treat acute myeloid leukemia and chronic lymphocytic leukemia in adults 75 years of age or older, or in people with other conditions that prevent the use of intensive induction chemotherapy. Usually given once daily in combination with azacytidine, decitabine, or low-dose cytarabine, the tablets should be swallowed whole and not crushed, chewed, or broken before swallowing.

The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).